Amarin Corporation plc Sponsored ADR

Amarin Corporation plc Sponsored ADR represents shares of a global pharmaceutical company focused on cardiovascular health. Headquartered in Dublin, Ireland, Amarin today concentrates on the commercialization and development of prescription therapeutics designed to reduce cardiovascular risk and improve cardiometabolic outcomes. Its primary product is Vascepa, an omega-3-based prescription medicine used in cardiovascular care and lipid management for adult patients. Amarin operates within the healthcare and pharmaceuticals sector, with activities centered on a single business segment: the marketing and distribution of cardiovascular pharmaceutical products to physicians, hospitals, and pharmacies across multiple international markets. Through its sponsored ADR structure, the company provides international investors with exposure to its equity while it continues to support a branded, clinically validated therapy backed by extensive cardiovascular outcomes research and regulatory approvals in various regions. This positions Amarin Corporation plc as a specialized participant in the global cardiovascular therapeutics market, serving patients at elevated cardiovascular risk.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Mr. Aaron D. Berg

Employees

80

Headquarters

Dublin, Ireland

Website

www.amarincorp.com